Vir, GSK win emergency use OK for Covid-fighting antibody

Little more than a year after Vir Biotechnology Inc. decided to scan its antibody library for potential foes of the coronavirus responsible for the Covid-19 pandemic, the San Francisco company and partner GlaxoSmithKline plc won a Food and Drug Administration emergency use authorization for their drug to treat people who test positive and are at high risk of progressing to severe sickness. The drug, called sotrovimab, walks a fine Covid treatment line: The monoclonal antibody has not shown benefit…